Cargando…
Designing Studies for Epigenetic Biomarker Development in Autoimmune Rheumatic Diseases
In just a few years, the number of epigenetic studies in autoimmune rheumatic and inflammatory diseases has greatly increased. This is in part due to the need of identifying additional determinants to genetics to explain the pathogenesis and development of these disorders. In this regard, epigenetic...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sciendo
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895872/ https://www.ncbi.nlm.nih.gov/pubmed/36788968 http://dx.doi.org/10.2478/rir-2022-0018 |
_version_ | 1784881939995426816 |
---|---|
author | de la Calle-Fabregat, Carlos Rodríguez-Ubreva, Javier Cañete, Juan D. Ballestar, Esteban |
author_facet | de la Calle-Fabregat, Carlos Rodríguez-Ubreva, Javier Cañete, Juan D. Ballestar, Esteban |
author_sort | de la Calle-Fabregat, Carlos |
collection | PubMed |
description | In just a few years, the number of epigenetic studies in autoimmune rheumatic and inflammatory diseases has greatly increased. This is in part due to the need of identifying additional determinants to genetics to explain the pathogenesis and development of these disorders. In this regard, epigenetics provides potential mechanisms that determine gene function, are linked to environmental factors, and could explain a wide range of phenotypic variability among patients with these diseases. Despite the high interest and number of studies describing epigenetic alterations under these conditions and exploring their relationship to various clinical aspects, few of the proposed biomarkers have yet reached clinical practice. The potential of epigenetic markers is high, as these alterations link measurable features with a number of biological traits. In the present article, we present published studies in the field, discuss some frequent limitations in the existing research, and propose a number of considerations that should be taken into account by those starting new projects in the field, with an aim to generate biomarkers that could make it into the clinics. |
format | Online Article Text |
id | pubmed-9895872 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Sciendo |
record_format | MEDLINE/PubMed |
spelling | pubmed-98958722023-02-13 Designing Studies for Epigenetic Biomarker Development in Autoimmune Rheumatic Diseases de la Calle-Fabregat, Carlos Rodríguez-Ubreva, Javier Cañete, Juan D. Ballestar, Esteban Rheumatol Immunol Res Review In just a few years, the number of epigenetic studies in autoimmune rheumatic and inflammatory diseases has greatly increased. This is in part due to the need of identifying additional determinants to genetics to explain the pathogenesis and development of these disorders. In this regard, epigenetics provides potential mechanisms that determine gene function, are linked to environmental factors, and could explain a wide range of phenotypic variability among patients with these diseases. Despite the high interest and number of studies describing epigenetic alterations under these conditions and exploring their relationship to various clinical aspects, few of the proposed biomarkers have yet reached clinical practice. The potential of epigenetic markers is high, as these alterations link measurable features with a number of biological traits. In the present article, we present published studies in the field, discuss some frequent limitations in the existing research, and propose a number of considerations that should be taken into account by those starting new projects in the field, with an aim to generate biomarkers that could make it into the clinics. Sciendo 2022-10-20 /pmc/articles/PMC9895872/ /pubmed/36788968 http://dx.doi.org/10.2478/rir-2022-0018 Text en © 2022 Carlos de la Calle-Fabregat et al., published by Sciendo https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License. |
spellingShingle | Review de la Calle-Fabregat, Carlos Rodríguez-Ubreva, Javier Cañete, Juan D. Ballestar, Esteban Designing Studies for Epigenetic Biomarker Development in Autoimmune Rheumatic Diseases |
title | Designing Studies for Epigenetic Biomarker Development in Autoimmune Rheumatic Diseases |
title_full | Designing Studies for Epigenetic Biomarker Development in Autoimmune Rheumatic Diseases |
title_fullStr | Designing Studies for Epigenetic Biomarker Development in Autoimmune Rheumatic Diseases |
title_full_unstemmed | Designing Studies for Epigenetic Biomarker Development in Autoimmune Rheumatic Diseases |
title_short | Designing Studies for Epigenetic Biomarker Development in Autoimmune Rheumatic Diseases |
title_sort | designing studies for epigenetic biomarker development in autoimmune rheumatic diseases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895872/ https://www.ncbi.nlm.nih.gov/pubmed/36788968 http://dx.doi.org/10.2478/rir-2022-0018 |
work_keys_str_mv | AT delacallefabregatcarlos designingstudiesforepigeneticbiomarkerdevelopmentinautoimmunerheumaticdiseases AT rodriguezubrevajavier designingstudiesforepigeneticbiomarkerdevelopmentinautoimmunerheumaticdiseases AT canetejuand designingstudiesforepigeneticbiomarkerdevelopmentinautoimmunerheumaticdiseases AT ballestaresteban designingstudiesforepigeneticbiomarkerdevelopmentinautoimmunerheumaticdiseases |